ALEC
Bearish signalScored 2026-09-09 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Alector, Inc.
- Nom
- Alector, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $198.2M
- Employés
- 103
- PDG
- Arnon Rosenthal
- Site web
- https://www.alector.com
- Marché
- ABOSAPLTCRBPFATEIRDMOLN
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 72 606 titres (~193 473,21 $ US)
- Insiders
- Rosenthal Arnon
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$296,087
Avg sell (VWAP, 90d window) $2.66 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-03
- Last synced
-
2026-09-09 09:58:02
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Wong-Sarad Grace | Sell · S | 3,625 | $2.51 | $9,094 | Form 4 |
| 2026-09-03 | Berkley Neil Lindsay | Sell · S | 29,251 | $2.66 | $77,948 | Form 4 |
| 2026-09-03 | Rosenthal Arnon | Sell · S | 72,606 | $2.66 | $193,473 | Form 4 |
| 2026-09-03 | Wong-Sarad Grace | Sell · S | 5,165 | $2.67 | $13,767 | Form 4 |
| 2026-09-02 | Wong-Sarad Grace | Sell · S | 656 | $2.75 | $1,804 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-09 Drivers: fundamentals. Moteurs : fondamentaux.
ALEC presents a deeply unfavorable risk profile, combining severe financial distress (liquidity score: 45, fundamentals trend score: 15) with a strongly negative catalyst backdrop (catalyst score: 15).
The first sentence of the analysis written for ALEC on 2026-09-09 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 3.83 · operating margin -693% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 54.1% | -84.9% | 90.9% | 100.0% | 8.5% | |
| Ebit Margin | -678.4% | -118.3% | -129.0% | -97.3% | -17.5% | |
| Ebitda Margin | -632.5% | -109.5% | -119.9% | -91.0% | -13.5% | |
| Operating Profit Margin | -692.8% | -144.2% | -156.3% | -103.2% | -18.0% | |
| Pretax Profit Margin | -678.4% | -118.3% | -129.0% | -97.3% | -17.5% | |
| Continuous Operations Profit Margin | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | |
| Net Profit Margin | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | |
| Bottom Line Profit Margin | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | |
| Current Ratio | 3.834 | 3.397 | 3.180 | 7.744 | 5.372 | |
| Quick Ratio | 3.834 | 3.397 | 3.180 | 7.744 | 5.372 | |
| Solvency Ratio | -0.508 | -0.323 | -0.249 | -0.218 | -0.055 | |
| Cash Ratio | 0.947 | 0.264 | 0.419 | 1.645 | 2.359 | |
| Price To Earnings Ratio | -1.122 | -1.537 | -5.115 | -5.698 | -45.889 | |
| Price To Earnings Growth Ratio | -0.086 | 0.073 | 1.381 | -0.022 | 0.562 | |
| Forward Price To Earnings Growth Ratio | -0.086 | 0.073 | 1.381 | -0.022 | 0.562 | |
| Price To Earnings Diluted Ratio | -1.122 | -1.537 | -5.115 | -5.698 | -45.889 | |
| Price To Earnings Diluted Growth Ratio | -0.086 | 0.073 | 1.381 | -0.022 | 0.562 | |
| Price To Book Ratio | 5.243 | 1.440 | 4.981 | 3.550 | 5.522 | |
| Price To Sales Ratio | 7.635 | 1.815 | 6.884 | 5.697 | 8.019 | |
| Price To Free Cash Flow Ratio | -0.873 | -0.790 | -3.582 | -31.137 | 5.623 | |
| Price To Operating Cash Flow Ratio | -0.873 | -0.794 | -3.628 | -37.443 | 5.562 | |
| Debt To Assets Ratio | 0.124 | 0.091 | 0.063 | 0.055 | 0.058 | |
| Debt To Equity Ratio | 1.182 | 0.335 | 0.290 | 0.202 | 0.158 | |
| Debt To Capital Ratio | 0.542 | 0.251 | 0.225 | 0.168 | 0.137 | |
| Long Term Debt To Capital Ratio | 0.233 | 0.069 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 9.568 | 3.693 | 4.635 | 3.673 | 2.709 | |
| Working Capital Turnover Ratio | 0.085 | 0.292 | 0.190 | 0.215 | 0.430 | |
| Operating Cash Flow Ratio | -2.648 | -1.838 | -1.035 | -0.217 | 2.139 | |
| Operating Cash Flow Sales Ratio | -8.745 | -2.286 | -1.897 | -0.152 | 1.442 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.005 | 1.013 | 1.203 | 0.989 | |
| Debt Service Coverage Ratio | -364.120 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -502.817 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -5.079 | -5.407 | -4.732 | -0.469 | 6.272 | |
| Capital Expenditure Coverage Ratio | -4,488.561 | -183.191 | -77.346 | -4.938 | 91.947 | |
| Dividend Paid And Capex Coverage Ratio | -4,488.561 | -183.191 | -77.346 | -4.938 | 91.947 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.985 | -1.745 | -5.438 | -5.348 | -49.227 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 54.1% | ▲139.0% | ▲20.4% |
| Ebit Margin | -678.4% | ▼-560.1% | ▼-470.3% |
| Ebitda Margin | -632.4% | ▼-523.0% | ▼-439.2% |
| Operating Profit Margin | -692.8% | ▼-548.6% | ▼-469.9% |
| Pretax Profit Margin | -678.4% | ▼-560.1% | ▼-470.3% |
| Continuous Operations Profit Margin | -679.2% | ▼-560.8% | ▼-469.3% |
| Net Profit Margin | -679.2% | ▼-560.8% | ▼-469.3% |
| Bottom Line Profit Margin | -679.2% | ▼-560.8% | ▼-469.3% |
| Current Ratio | 3.834 | ▲0.437 | ▼-0.872 |
| Quick Ratio | 3.834 | ▲0.437 | ▼-0.872 |
| Solvency Ratio | -0.507 | ▼-0.185 | ▼-0.237 |
| Cash Ratio | 0.947 | ▲0.683 | ▼-0.180 |
| Price To Earnings Ratio | -1.122 | ▲0.414 | ▲10.750 |
| Price To Earnings Growth Ratio | -0.086 | ▼-0.159 | ▼-0.468 |
| Forward Price To Earnings Growth Ratio | -0.086 | ▼-0.159 | ▼-0.468 |
| Price To Earnings Diluted Ratio | -1.122 | ▲0.414 | ▲10.750 |
| Price To Earnings Diluted Growth Ratio | -0.086 | ▼-0.159 | ▼-0.468 |
| Price To Book Ratio | 5.242 | ▲3.803 | ▲1.096 |
| Price To Sales Ratio | 7.635 | ▲5.820 | ▲1.625 |
| Price To Free Cash Flow Ratio | -0.873 | ▼-0.083 | ▲5.279 |
| Price To Operating Cash Flow Ratio | -0.873 | ▼-0.079 | ▲6.562 |
| Debt To Assets Ratio | 0.124 | ▲0.033 | ▲0.045 |
| Debt To Equity Ratio | 1.182 | ▲0.847 | ▲0.749 |
| Debt To Capital Ratio | 0.542 | ▲0.291 | ▲0.277 |
| Long Term Debt To Capital Ratio | 0.233 | ▲0.164 | ▲0.173 |
| Financial Leverage Ratio | 9.568 | ▲5.874 | ▲4.712 |
| Working Capital Turnover Ratio | 0.085 | ▼-0.208 | ▼-0.158 |
| Operating Cash Flow Ratio | -2.648 | ▼-0.809 | ▼-1.928 |
| Operating Cash Flow Sales Ratio | -8.745 | ▼-6.458 | ▼-6.417 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.005 | ▼-0.042 |
| Debt Service Coverage Ratio | -364.120 | ▼-364.120 | ▼-291.296 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -502.817 | ▼-502.817 | ▼-402.254 |
| Operating Cash Flow Coverage Ratio | -5.079 | ▲0.328 | ▼-3.196 |
| Capital Expenditure Coverage Ratio | -4488.561 | ▼-4305.370 | ▼-3556.143 |
| Dividend Paid And Capex Coverage Ratio | -4488.561 | ▼-4305.370 | ▼-3556.143 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.985 | ▲0.760 | ▲11.563 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $160.7M | $182.6M | $668.2M | $761.2M | $1.66B | |
| Enterprise value | $131.1M | $192.0M | $632.6M | $650.2M | $1.38B | |
| EV / Sales | 6.23x | 1.91x | 6.52x | 4.87x | 6.66x | |
| EV / Op. cash flow | -0.71x | -0.83x | -3.44x | -31.98x | 4.62x | |
| EV / Free cash flow | -0.71x | -0.83x | -3.39x | -26.60x | 4.67x | |
| EV / EBITDA | -0.98x | -1.75x | -5.44x | -5.35x | -49.23x | |
| Net debt / EBITDA | 0.22x | -0.09x | 0.31x | 0.91x | 10.05x | |
| Current ratio | 3.83x | 3.40x | 3.18x | 7.74x | 5.37x | |
| Income quality | 1.29x | 1.93x | 1.41x | 0.15x | -8.22x | |
| Graham net-net | -$0 | $1 | $1 | $2 | $3 | |
| Tax burden | 100.1% | 100.1% | 104.2% | 102.5% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $196.9M | $299.8M | $387.9M | $632.6M | $610.2M | |
| Invested capital | $221.5M | $336.9M | $434.9M | $686.0M | $668.1M | |
| Return on assets | -48.7% | -25.4% | -21.0% | -16.9% | -4.5% | |
| Operating ROA | -38.3% | -26.6% | -21.5% | -17.2% | -5.7% | |
| Return on tangible assets | -48.7% | -25.4% | -21.0% | -16.9% | -4.5% | |
| Return on equity | -466.3% | -93.9% | -97.2% | -62.2% | -12.1% | |
| Return on invested capital | -62.5% | -41.2% | -33.5% | -19.6% | -5.5% | |
| Return on capital employed | -65.2% | -42.2% | -34.2% | -19.9% | -5.5% | |
| Earnings yield | -89.0% | -65.2% | -19.5% | -17.5% | -2.2% | |
| Free cash flow yield | -114.6% | -126.6% | -27.9% | -3.2% | 17.8% | |
| Capex / Op. cash flow | -0.0% | -0.5% | -1.3% | -20.3% | 1.1% | |
| Capex / Depreciation | 0.4% | 14.2% | 26.9% | 48.6% | 39.0% | |
| Capex / Sales | 0.2% | 1.2% | 2.5% | 3.1% | 1.6% | |
| SG&A / Sales | 256.5% | 57.1% | 58.4% | 45.7% | 26.6% | |
| R&D / Sales | 584.8% | 208.1% | 197.9% | 157.5% | 91.5% | |
| Stock comp / Sales | 126.7% | 39.2% | 44.1% | 34.5% | 19.7% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 7d | 13d | |
| Days payables outstanding | 64d | 4d | 156d | 0d | 9d | |
| Operating cycle | 0d | 0d | 0d | 7d | 13d | |
| Cash conversion cycle | -64d | -4d | -156d | 7d | 4d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-08 Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT) Alector (NASDAQ: ALEC - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares Alector and Sarepta Therapeutics'' net
- 2026-09-03 Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York) Thursday, September 10, 2026, at 2:10 p.m.
- 2026-08-06 Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.3 per share a year ago.
- 2026-08-06 Alector Reports Second Quarter 2026 Financial Results and Provides Business Update Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector''s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer''s disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson''s disease (PD)).
- 2026-07-08 Alector and GSK partnership to end after dementia, Alzheimer''s drug failures Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.